Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 5302) — Amsterdam, North Holland

Public research footprint of Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 5302), compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Most-studied conditions

Advanced Solid Tumors · Breast Neoplasms · Metastatic Castration-Resistant Prostate Cancer · Carcinoma, Renal Cell

Recently updated registry entries

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer… (Recruiting)
NCT04626518 — Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With… (Active Not Recruiting)
NCT04626479 — Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 5302)?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.